Use the menu on the left to select another section to read.

RESEARCH NEWS

Barbara Entwisle named vice chancellor for research

UNC breast cancer program recognized as national model

UNC study: common transplant drug inhibits breast cancer growth

entwisle_barbara-small

Barbara Entwisle

Barbara Entwisle named vice chancellor for research

Barbara Entwisle, Kenan Distinguished Professor of Sociology who has been a leading researcher at UNC for 26 years, has been appointed as the vice chancellor for research.

“Barbara has been a great addition to our administrative team and already has effectively championed the University’s research enterprise in her interim role,” said Chancellor Holden Thorp. “She brings extensive experience in leading the Carolina Population Center, one of our most distinguished research units. She understands multidisciplinary research – a hallmark of this University – extraordinarily well and has the skills and insights we need to help keep Carolina competitive nationally.”

Entwisle succeeds Tony Waldrop, who served as vice chancellor until leaving last summer to become provost and vice president for academic affairs at the University of Central Florida.

As vice chancellor, Entwisle leads a campus-wide research program that attracted $803 million in contract and grant funding in fiscal 2010 – more than double the amount from a decade ago. Helping spur that growth has been the construction, made possible in recent years by public and private investments, of key research facilities including the Carolina Physical Science Complex. The vice chancellor leads efforts to connect academic units across the campus with University priorities and manages research support offices as well as select centers and institutes.

Entwisle, a social demographer who studies population, health and environment, joined Carolina’s department of sociology in 1985. From 2002 until last summer, she directed the Carolina Population Center, and within the last decade assumed additional faculty appointments in the department of geography, curriculum for the environment and ecology, curriculum in international and area studies, and department of Asian studies.

More: http://uncnews.unc.edu/content/view/4408/68/

Back to top

UNC breast cancer program recognized as national model

A UNC study has joined the ranks of an elite group of programs recognized for their contributions to reducing cancer.

The North Carolina Breast Cancer Screening Program, based at UNC’s Lineberger Comprehensive Cancer Center, has been designated a Research-tested Intervention Program by the National Cancer Institute.

The program – which began in 1993 and was active in the community for 10 years – was designed to reduce breast cancer in older African-American women living in eastern North Carolina. It addressed disparities in breast cancer rates between African American and white women due to later-stage diagnosis of the disease among black women. Now, other researchers and public health practitioners use the study’s data and materials to design new interventions.

During the decade-long study, the program trained more than 200 community members from five rural eastern North Carolina counties (Beaufort, Bertie Martin, Tyrrell and Washington) as lay health advisors or community outreach specialists, promoting routine mammography screening among women 50 years and older; in the community it was known as the Save our Sisters program.

More: http://bit.ly/jNGDca

Back to top

UNC study: common transplant drug inhibits breast cancer growth

klauber-demore

Nancy Klauber-More

Neil Boyd

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26 “Public Library of Science.”

Nancy Klauber-DeMore, associate professor of surgery, said, " We now have a rationale for performing human clinical trials to determine if Tacrolimus reduces breast cancer growth in humans. Since Tacrolimus is already an FDA-approved drug, the safety and toxicity profile is known, which means that Tacrolimus could potentially go directly into a later stage clinical trial."

More: http://news.unchealthcare.org/news/2011/may/tacrolimus

Back to top